Literature DB >> 16856035

Screening programmes for the early detection and prevention of oral cancer.

O Kujan1, A M Glenny, R J Oliver, N Thakker, P Sloan.   

Abstract

BACKGROUND: Screening programmes for major cancers, such as breast and cervical cancer have effectively decreased the mortality rate and helped to reduce the incidence of these cancers. Although oral cancer is a global health problem with increasing incidence and mortality rates, no national population-based screening programmes for oral cancer have been implemented. To date there is debate on whether to employ screening methods for oral cancer in the daily routine work of health providers.
OBJECTIVES: To assess the effectiveness of current screening methods in decreasing oral cancer mortality. SEARCH STRATEGY: Electronic databases (MEDLINE, CANCERLIT, EMBASE, the Cochrane Central Register of Controlled Trials; 1966 to July 2005, The Cochrane Library - Issue 3, 2005), bibliographies, handsearching of specific journals and contact authors were used to identify published and unpublished data. SELECTION CRITERIA: Randomised controlled trials of screening for oral cancer or precursor oral lesions using visual examination, toluidine blue, fluorescence imaging or brush biopsy. DATA COLLECTION AND ANALYSIS: The search found 112 citations and these have been reviewed. One randomised controlled trial of screening strategies for oral cancer was identified as meeting the review's inclusion criteria. Validity assessment, data extraction and statistics evaluation were undertaken by two independent review authors. MAIN
RESULTS: One 10-year randomised controlled trial has been included (n = 13 clusters: 191,873 participants). There was no difference in the age-standardised oral cancer mortality rates for the screened group (16.4/100,000 person-years) and the control group (20.7/100,000 person-years). Interestingly, a significant 34% reduction in mortality was recorded in high-risk subjects between the intervention cohort (29.9/100,000 person-years) and the control arm (45.4/100,000). However, this study has some methodological weaknesses. Additionally, the study did not provide any information related to costs, quality of life or even harms of screening from false-positive or false-negative findings. AUTHORS'
CONCLUSIONS: Given the limitation of evidence (only one included randomised controlled trial) and the potential methodological weakness of the included study, it is valid to say that there is insufficient evidence to support or refute the use of a visual examination as a method of screening for oral cancer using a visual examination in the general population. Furthermore, no robust evidence exists to suggest that other methods of screening, toluidine blue, fluorescence imaging or brush biopsy, are either beneficial or harmful. Future high quality studies to assess the efficacy, effectiveness and costs of screening are required for the best use of public health resources. In addition, studies to elucidate the natural history of oral cancer, prevention methods and the effectiveness of opportunistic screening in high risk groups are needed. Future studies on improved treatment modalities for oral cancer and precancer are also required.

Entities:  

Mesh:

Year:  2006        PMID: 16856035     DOI: 10.1002/14651858.CD004150.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  22 in total

1.  Demographics and efficacy of head and neck cancer screening.

Authors:  Andrew G Shuman; Payam Entezami; Anna S Chernin; Nancy E Wallace; Jeremy M G Taylor; Norman D Hogikyan
Journal:  Otolaryngol Head Neck Surg       Date:  2010-09       Impact factor: 3.497

2.  Incidence and localization of abnormal mucosa findings in patients consulting ENT outpatient clinics and data analysis of a cancer registry.

Authors:  J Löhler; A O H Gerstner; F Bootz; L E Walther
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-10       Impact factor: 2.503

3.  Diagnostic efficiency of differentiating small cancerous and precancerous lesions using mucosal brush smears of the oral cavity--a prospective and blinded study.

Authors:  Felix Peter Koch; Martin Kunkel; Stefan Biesterfeld; Wilfried Wagner
Journal:  Clin Oral Investig       Date:  2010-07-01       Impact factor: 3.573

4.  Diffuse reflectance spectroscopy of epithelial tissue with a smart fiber-optic probe.

Authors:  Bing Yu; Amy Shah; Vivek K Nagarajan; Daron G Ferris
Journal:  Biomed Opt Express       Date:  2014-02-10       Impact factor: 3.732

5.  Perspectives of San Juan healthcare practitioners on the detection deficit in oral premalignant and early cancers in Puerto Rico: a qualitative research study.

Authors:  Douglas E Morse; Carmen M Vélez Vega; Walter J Psoter; Himilce Vélez; Carmen J Buxó; Linda S Baek; Augusto Elias; Melba Sánchez Ayendez
Journal:  BMC Public Health       Date:  2011-05-26       Impact factor: 3.295

Review 6.  Screening programmes for the early detection and prevention of oral cancer.

Authors:  Paul Brocklehurst; Omar Kujan; Lucy A O'Malley; Graham Ogden; Simon Shepherd; Anne-Marie Glenny
Journal:  Cochrane Database Syst Rev       Date:  2013-11-19

Review 7.  Exciting new advances in oral cancer diagnosis: avenues to early detection.

Authors:  Ravi Mehrotra; Dwijendra K Gupta
Journal:  Head Neck Oncol       Date:  2011-07-28

8.  Alcohol-folate interactions in the risk of oral cancer in women: a prospective cohort study.

Authors:  Jayapriyaa R Shanmugham; Athanasios I Zavras; Bernard A Rosner; Edward L Giovannucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-14       Impact factor: 4.254

9.  Regular dental visits are associated with earlier stage at diagnosis for oral and pharyngeal cancer.

Authors:  Scott M Langevin; Dominique S Michaud; Melissa Eliot; Edward S Peters; Michael D McClean; Karl T Kelsey
Journal:  Cancer Causes Control       Date:  2012-09-08       Impact factor: 2.506

10.  Oral cancer screening in the Bangladeshi community of Tower Hamlets: a social model.

Authors:  H Nunn; A Lalli; F Fortune; R Croucher
Journal:  Br J Cancer       Date:  2009-12-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.